3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Neuroblastoma
2
Lymphoma
2
Skin Neoplasms
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Osteosarcoma
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Metabolic Diseases
1
Mesothelioma, Malignant
1
Mesothelioma
1
Melanoma
1
Lymphoma, T-Cell
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunologic Deficiency Syndromes
1
Hepatoblastoma
1
Ganglioneuroblastoma
1
Anemia, Aplastic
1
Interventions
dinutuximab
3
Cyclophosphamide
3
Vincristine
2
Topotecan
2
Thiotepa
2
Temozolomide
2
Stem Cell Transplantation
2
Specimen Handling
2
Radiation
2
Platinum
2
Melphalan
2
Magnetic Resonance Spectroscopy
2
Isotretinoin
2
Irinotecan
2
Doxorubicin
2
Cisplatin
2
Carboplatin
2
Biopsy
2
1,2-diaminocyclohexaneplatinum II citrate
2
sargramostim
1
lorlatinib
1
fludarabine
1
etoposide phosphate
1
Transurethral Resection of Bladder
1
Razoxane
1
Radiotherapy
1
Proton Therapy
1
Nuclear Medicine Department, Hospital
1
Leukapheresis
1
Influenza Vaccines
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Ganglioneuroblastoma
×
Influenza Vaccines
×
Clear all
NCT07502287
2026-03-30
DUAL-NK-NB
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled